Leerink upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a $456 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
- Vertex Pharmaceuticals announces CASGEVY reimbursement agreement in Italy
- Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning
- Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
- FDA Draft Guidance Boosts Vertex Pharmaceuticals’ Prospects for Non-Opioid Analgesics